SCHEMBL471986

SCHEMBL471986

CN(C)C(Cc1ccc(O)c(O)c1)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM6B O15054 1/20 0.60
KDM4E B2RXH2 8/20 0.58
HSD17B10 Q99714 7/20 0.58
TDP1 Q9NUW8 7/20 0.58
ALOX15 P16050 6/20 0.58
RECQL P46063 6/20 0.58
HIF1A Q16665 4/20 0.58
USP2 O75604 4/20 0.58
PTGS2 P35354 3/20 0.58
FYN P06241 3/20 0.58
LCK P06239 3/20 0.58
ADORA3 P0DMS8 2/20 0.58
HTR2A P28223 2/20 0.58
EGFR P00533 2/20 0.58
PTGS1 P23219 1/20 0.58
SLC7A5 Q01650 1/20 0.58
HPGD P15428 6/20 0.53
MAPT P10636 6/20 0.53
POLB P06746 5/20 0.53
ALOX12 P18054 4/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29794141 1.00 KDM6B (0.60) KDM6BKDM4EHSD17B10TDP1ALOX15
SCHEMBL29913698 0.85 KDM6B (0.62) KDM6BKDM4EHSD17B10TDP1ALOX15
SCHEMBL11664157 0.84 KDM4E (0.59) KDM6BKDM4EHSD17B10TDP1ALOX15
SCHEMBL30130608 0.83 KDM6B (0.60) KDM6BKDM4EHSD17B10TDP1ALOX15
SCHEMBL31746120 0.83 KDM4E (0.63) KDM6BKDM4EHSD17B10TDP1ALOX15
SCHEMBL29504521 0.83 KDM6B (0.55) KDM6BKDM4EHSD17B10TDP1ALOX15
SCHEMBL12608303 0.81 KDM6B (0.50) KDM6BKDM4EHSD17B10TDP1ALOX15
SCHEMBL38225 0.81 SLC7A5 (0.55) SLC7A5MAPTALDH1A1ESR1SLC6A2
SCHEMBL21899391 0.81 SLC7A5 (0.55) SLC7A5MAPTALDH1A1ESR1SLC6A2
SCHEMBL38224 0.81 SLC7A5 (0.55) SLC7A5MAPTALDH1A1ESR1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180193209-A1 A POLYMER PRODUCT AND PREPARATION THEROF SINGAPORE HEALTH SERVICES PTE LTD. (SG) 2018-07-12 US claimed
EP-3319779-A1 A POLYMER PRODUCT AND PREPARATION THEREOF Singapore Health Services Pte Ltd (SG) 2018-05-16 EP claimed
EP-4731266-A1 NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES The Regents of the University of Michigan (US) 2026-04-29 EP disclosed
US-20260108618-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS CIDARA THERAPEUTICS, INC. 2026-04-23 US disclosed
US-12569565-B2 Compositions and methods for the treatment of viral infections CIDARA THERAPEUTICS, INC. (US) 2026-03-10 US disclosed
US-20260000781-A1 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS INC (US) 2026-01-01 US disclosed
US-20250325644-A1 ALK POLYPEPTIDES AND METHODS OF USE THEREOF ELICIO THERAPEUTICS INC (US) 2025-10-23 US disclosed
EP-4627079-A2 THERMOSTABLE BINDING SCAFFOLDS Nectagen, Inc. (US) 2025-10-08 EP disclosed
US-12427200-B2 Compositions and methods for the treatment of viral infections CIDARA THERAPEUTICS, INC. (US) 2025-09-30 US disclosed
US-12370245-B2 ALK polypeptides and methods of use thereof Elicio Therapeutics, Inc. (US) 2025-07-29 US disclosed
US-20250177503-A1 COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2025-06-05 US disclosed
WO-2008098280-A1 METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN GROWTH HORMONE PEPTIDES POLYCHIP PHARMACEUTICALS PTY LTD (AU) 2008-08-21 WO disclosed
WO-2008077194-A1 RECEPTOR AGONISTS XENOME LTD (AU) 2008-07-03 WO disclosed
US-7312195-B2 Cyclised conotoxin peptides THE UNIVERSITY OF QUEENSLAND (AU) 2007-12-25 US disclosed
WO-2007118270-A1 CYCLISED ALPHA-CONOTOXIN PEPTIDES THE UNIVERSITY OF QUEENSLAND (AU) 2007-10-25 WO disclosed
US-20060270832-A1 Novel x-conotoxin peptides (-II) XENOME LIMITED (AU) 2006-11-30 US disclosed
US-20050256301-A1 Cyclised conotoxin peptides THE UNIVERSITY OF QUEENSLAND (AU) 2005-11-17 US disclosed
EP-1578787-A1 NOVEL CHI-CONOTOXIN PEPTIDES (-II) Xenome Ltd (AU) 2005-09-28 EP disclosed
WO-2004099238-A1 NOVEL mu-CONOTOXIN PEPTIDES THE UNIVERSITY OF QUEENSLAND (AU) 2004-11-18 WO disclosed
WO-2004050688-A1 NOVEL χ-CONOTOXIN PEPTIDES (-II) XENOME LTD (AU) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12427200-B2 Compositions and methods for the treatment of viral infections FCGR3B, ALB, FCGR1A KDM6B 4446/4885KDM4E 4753/4885HSD17B10 4645/4885
US-20050256301-A1 Cyclised conotoxin peptides VIP, CANX, IAPP KDM6B 4504/4885KDM4E 4489/4885HSD17B10 2676/4885
US-20260108618-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS FCGR3B, FCGR1A, FCGR2A KDM6B 539/4885KDM4E 1225/4885HSD17B10 4780/4885
US-12569565-B2 Compositions and methods for the treatment of viral infections ALB, FCGR3B, FCGR1A KDM6B 1093/4885KDM4E 1470/4885HSD17B10 4784/4885
US-20260000781-A1 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF FCGR2A, FCGR1A, FCGR3B KDM6B 1249/4885KDM4E 1204/4885HSD17B10 2909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.